Quick Answer
Iterum Therapeutics plc reported Operating Income of -$18.70 million for fiscal year 2024.
Iterum Therapeutics plc Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$18.70M | +60.6% |
| 2023 | -$47.47M | -56.2% |
| 2022 | -$30.38M | -23.8% |
| 2021 | -$24.54M | +23.6% |
| 2020 | -$32.13M | +68.5% |
| 2019 | -$102.02M | -33.3% |
| 2018 | -$76.56M | -159.9% |
| 2017 | -$29.45M | -120.5% |
| 2016 | -$13.36M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.73M | -58.2% | -39.8% |
| June 30, 2025 | -$5.53M | -39.1% | -49.0% |
| March 31, 2025 | -$3.71M | +39.8% | +24.1% |
| September 30, 2024 | -$4.89M | +70.7% | -22.9% |
| June 30, 2024 | -$3.98M | +63.3% | +35.5% |
| March 31, 2024 | -$6.16M | +27.7% | +63.1% |
| September 30, 2023 | -$16.68M | -137.2% | -54.2% |
| June 30, 2023 | -$10.82M | -34.4% | -26.9% |
- Iterum Therapeutics plc showed an increase of +60.6% in Operating Income compared to the prior fiscal year.
- Over the 2016–2024 period, Iterum Therapeutics plc’s operating income has declined by 40.0% (from -$13.36 million to -$18.70 million).
- The most recent figure is from Iterum Therapeutics plc’s fiscal year 2024 report (Form 10-K), filed with the SEC on February 7, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: